Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boiler room called the drop from $9.80... Weeeeeeeeeee
Wow VRNA has some serious potential here. I could see this one just taking off.
Sell this listen to me I will make you rich!!! This not good ticker better sell before tanks!
Lol no way dump this turd bud...
Tanking bud be careful
I hope it holds! Currently $9.74 at 8:13 am in NY.
VRNA is a great $$$$$ opportunity.
COPD market is priceless. Billions, billions, and billions.
Agree! > $20.00+ closing bell target!
Fantastic day, I mean, the best of the best. London Exchange closed at 60 dollars and we are still at 10.00. Wait till conference call, investors will flock here soon.
Going to be a great day for VRNA > $$$$$
VRNA is a great $$$$$ opportunity.
What > that is HUGE > VRNA!
Looks like it closed $60 London Exchange.
nailed it>?
trading opened 7am in US
your a pissa
Fantastic News, one of the best news I have seen in a longest time, this should be sitting at 600-800 million market cap minimum by Wednesday. After Phase 3 this should and will sit at 5 billion market cap. Here is why: Annual cost is 14,000 dollars for each patient, lets just say, they covered only 400,000 patients that will equate to almost 5 billion dollars and this is only in the US, numbers haven’t even been considered if we take China and Europe in the equation. now this is not me saying this, this is a direct quote from the company based on their presentation. Remember folks, a game changing therapy, in the COPD, Asthma and other respiratory conditions, they met all the primary points from the lowest dosage to the highest, which means they didn’t even have to tweak it, means every dosage worked. After phase 3 this company with the current share structure is worth 400 dollars. I also want to mention the fact, based on the 20-F filings, they have enough cash to last them all the way through September 2020. There is no other therapy like this out there that works so efficiently and doing multiple things at the same time. I potentially see this running like KR*TX and even by far better than CR*TX. The market is going to price this accordingly starting today and I won’t be at all surprise to see this hitting all cylinders today and all this week, especially the fact that they are making conference call with big investment community about their findings. One of the most important thing I like about this ticker is, virtually under the radar (Unknown), but that will change today and now, the other thing is the share structure is minimal, 13 million OS and float 4 million float, they have it low for a reason, they believe in their pipeline and they want big investors to pay a hefty price for these shares. Here is another comparison VR*TX is a 50 billion dollar market cap, if this therapy is as good as the data claims to be, so I ask, what would be a justified market cap after all is said and done. The most important thing one needs to realize, almost everyone has a family member that is effected by COPD, this is a huge, huge market, ginormous. Bottom line, anyone sell before 50 dollars definitely has to be out of their minds. I see a huge potential run, once the investment community gets to read the presentation and listens to the conference call and reads the data, you will be glad you held. This is short, mid and long term hold, the best of the best. This is like owning early stage pharma, that will make you 6-7 figures in a very short period of time. They could be bought out by a big fish Pharma for a hefty price before they even get to Phase 3 completion. Price tag anywhere between 3-5 billion dollars. With all that said, I haven’t even considered partnership announcement that could and should mitigate any secondary offering before they run out cash (enough cash in hand that will last them till September 2020). This is a strongest buy and forget about it.
https://www.veronapharma.com/media/verona-pharma-reports-positive-top-line-data-4-week-phase-2b
https://www.veronapharma.com/about
https://ether-assets.ams3.cdn.digitaloceanspaces.com/verona-pharma/VRNA_Investor_Presentation_Jefferies_17_Nov_2019.pdf?mtime=20191205143905
Analyst Coverage
https://www.veronapharma.com/investors/investor-information
Product Pipeline
https://www.veronapharma.com/ensifentrine#ourPipeline
Media Coverage
https://www.veronapharma.com/media
institution ownership which shows they control the float too.
https://finance.yahoo.com/quote/VRNA/holders?p=VRNA
$VRNA-Verona Pharma Shares Up 58% Premarket on Positive Topline Results
6:09 AM ET 1/13/20 | Dow Jones
By Chris Wack
Verona Pharma Plc (VRNA) shares rose 58% to $9.42 premarket after the company said it saw positive top-line data from a study evaluating nebulized ensifentrine as an add-on treatment to tiotropium Spiriva Respimat in patients with moderate to severe chronic obstructive pulmonary disease.
The biopharmaceutical said the study met its primary endpoint of improved lung function, with ensifentrine added on to inhaled tiotropium, commonly used to treat COPD.
Ensifentrine produced a clinically and statistically significant, and dose-dependent improvement in peak forced expiratory volume in one second at week 4 compared to placebo added on to tiotropium.
Verona said the primary endpoint was met at all doses, and ensifentrine was well tolerated at all doses with an adverse event profile similar to placebo.
Write to Chris Wack at chris.wack@wsj.com
$VRNA I agree bud
$VRNA gonna go parabolic on Monday! If it was bad news, they would have dropped it Friday a/hs. New drug going to phase 3 and will revolutionize CF , COPD and asthma treatment. May see $20+!this week.
Wake up People!
[url][/url][tag] https://markets.businessinsider.com/news/stocks/big-day-awaits-verona-pharma-vrna-on-monday-1028810407[/tag]
Wake up People!
[url][/url][tag] https://markets.businessinsider.com/news/stocks/big-day-awaits-verona-pharma-vrna-on-monday-1028810407[/tag]
Nice pre market move to $6.59. PR released with VRNA appointing David Moskowitz as VP, Capital Markets Strategy and Investor Relations.
Hoping the rumor of good news is true. Enjoying the upward trend!
GLTA!
Nice Positive Day. Something changed or someone knows news is coming.
According to Dr. Ebsworth, the results of Phase 2B will be early this year. Not sure why they said Early 2019. Think that was too optimistic.
Great to see the selling stop. Now we just wait for news and wait for the fireworks and everyone to join the show.
* * $VRNA Video Chart 12-27-2019 * *
Link to Video - click here to watch the technical chart video
Any news on the phase 2 data?
Phase 2b results imminent + extreme low float = $10+ coming
Loadup guys before the clinical results hit the wire which could push this ultra low float gem to $10+
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
195
|
Created
|
12/03/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |